The Pharmagellan Guide to Biotech Forecasting and Valuation

by Frank S. David, Seth Robey (Contributor), Andrew Matthews (Contributor)

** Get info on bulk orders & how to get a free chapter at **

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to build and analyze forecasts and valuations of R&D-stage drugs. This book is for you. The Pharmagellan Guide to Biotech Forecasting and Valuation is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage assets and companies. Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.

Genres: Finance, Biology, Business

138 pages, Paperback

Published January 4, 2017

About the author

I'm a biopharma advisor at Pharmagellan who specializes in R&D strategy.

As an author, I want to help experts in and around the drug industry interpret clinical results and estimate the value of drugs in development.

Read my book ratings for my must-read recs for biopharma pros and newbies.

Please sign up for my free biotech newsletter on the Pharmagellan website!

Reviews

[Tor Alm · Rating 5 out of 5]

This book is a must read for everyone working with investment decisions for R&D programs.

This covers many essential areas and financial biotech modelling. What I am missing is:

1) more nuance around Europe and RoW
2) more nuance around orphan
3) more nuance on biosimilars
4) a chapter on ATMPs

This book is starting to feel a little bit dated, so I hope a new edition comes along! I would buy it for sure 😊

[Charles · Rating 5 out of 5]

Sure, it's not cheap for a book of only 100 pages. But the information contained in the Pharmagellan Guide is straight to-the-point. There isn't any fluff (I can't say the same for some 1,000+ page textbooks). I strongly recommend this book to anyone involved in biotech or pharma valuation.

One particularly useful component: the citations and Pharmagellan's analyses. For example, Pharmagellan did a study of clinical trial success times, which you can incorporate into your valuation models.

[Naina Z. · Rating 3 out of 5]

This reads like a graduate student’s thesis (the references were 1/4 of the book). The information was useful and there was evidence to back all assumptions which is half the battle in early biotechs but I felt like there could’ve been much more done to make this a more encompassing resource (esp on the valuation section). Still, this was one of the first books published specific to biotech modelling and I think it would be helpful to those early in the field.

[Hamish Lou · Rating 4 out of 5]

Packed with data backed ideas and methodologies, and as many have said - straight to the point, no fluff.

Disclaimer: Does not actually go through a model with you, but describes the different parts that you’ll need to consider when constructing one

[Ritika Das · Rating 4 out of 5]

Quick review of inputs that matter in biotech valuation based on disease indication and other variables. Easy to read and valuable for a quick reference while building a model.

[andrew y · Rating 3 out of 5]

Barely straddling the line between overpriced repetition of public domain information and necessary reading for those trying to get into the forecasting conversation.